Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 dose-finding study in type 2 diabetes mellitus with heart failure
NL-OMON45545Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) (5 arms), sponsored by Novartis. Primary endpoint: Change in NT-proBNP at 12 weeks. Started Jan 2018; status: active, not recruiting.
02
Drugs
licogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON45545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45545.